Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

0.7350
-0.0037-0.50%
Pre-market: 0.75550.0205+2.79%08:55 EDT
Volume:356.18K
Turnover:260.82K
Market Cap:14.46M
PE:-0.94
High:0.7580
Open:0.7580
Low:0.7200
Close:0.7387
52wk High:3.78
52wk Low:0.7200
Shares:19.67M
Float Shares:18.13M
Volume Ratio:0.64
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7779
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-39.29%
PB:-25.78
PE(LYR):-0.61

Loading ...

Dare Bioscience closes Reg A offering, issues 20,000 units at $5 each

Reuters
·
Apr 21

Dare Bioscience reclassifies director Gregory Matz to Class III board seat

Reuters
·
Apr 18

Daré Bioscience announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 18

Daré Bioscience completes Regulation A sale of 3,470 units at $5 each

Reuters
·
Apr 14

Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Apr 11

Bayer’s Double-DARE Prostate Cancer Study Builds Real-World Case for Nubeqa

TIPRANKS
·
Apr 02

Dare Bioscience Q4 EPS $(0.02) Beats $(0.43) Estimate, Sales $1.024M Beat $375.750K Estimate

Benzinga Earnings
·
Mar 27

Dare Bioscience FY2025 net loss widens 231% to $(13.0) million; revenue climbs 10,429% to $1.0 million

Reuters
·
Mar 27

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Mar 27

Dare Bioscience Inc expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
Mar 25

On National Viagra Day, Women Finally Claim Their Turn:

GlobeNewswire
·
Mar 23

Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

GlobeNewswire
·
Mar 20

Daré Bioscience completes Regulation A sale of 43,050 investor units at USD 5 each

Reuters
·
Mar 18

Dare Bioscience receives NIH funding award notice for DARE-PTB1

TIPRANKS
·
Mar 16

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

GlobeNewswire
·
Mar 16

FDA clears Daré Bioscience IND for DARE-HPV Phase 2 study

Reuters
·
Mar 12